Spero Therapeutics Inc., of Cambridge, Mass., priced its IPO of 5.5 million shares at $14 per share, the low end of its previously proposed range, for gross proceeds of $77 million. The company granted underwriters a 30-day option to purchase up to 825,000 additional common shares, which could add up to $11.6 million to the proceeds.